Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsUpgradesPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Stifel analyst Jonathan Block upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $22 to $26.
Stifel analyst Jonathan Block upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $22 to $26.
